Fast Company: How open-source medicine could prepare us for the next pandemic

A study on drug repurposing co-authored by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. The study found that “about 31 per cent of drugs approved by the FDA had the potential to treat an illness similar in nature to the original target disease, with a 67 per cent success rate.” But it’s much harder to repurpose an existing drug to treat a fundamentally different disease – study found that “only 18 per cent of drugs had potential in that capacity, with a 33 per cent success rate.”

Read the full article [fastcompany.com]